Skip to content
Back to meeting Original
Stanley Zhou· @stanleytor · X·· 2 days agoScore70

LITESPARK-012

Body · original

LITESPARK-012 data showing adding belzutifan or anti-CTLA to pembro / lenvatinib does not really improve outcome may be one of my favorites from ESMO.

Negative data is just as important.

#ESMO2026

5 views · 0 likes · 0 reposts · 0 replies

Source: Stanley Zhou · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org

Disclaimer CBA Frontier Insights uses AI-assisted methods to aggregate, summarize, and analyze publicly accessible biopharmaceutical information. Content is provided for informational and educational purposes only and does not represent the official views of original sources or affiliated organizations. AI-generated content may contain errors; please verify important information against primary sources. Intellectual property rights remain with their respective owners. For copyright concerns or corrections, please contact us through the website’s feedback page.